Takeda Pharmaceutical Co Ltd 2020 SR
The report outlines Takeda's commitment to purpose-led sustainability, focusing on patients, people, and the planet. Key highlights include achieving carbon neutrality for FY2019 through offsets and setting a target for net-zero operations by 2040. The company invested ¥492.4 billion in R&D, focusing on four core therapeutic areas, and reached over 70,000 patients in underserved communities through access programs. Takeda also responded to the COVID-19 pandemic by co-founding the CoVIg-19 Plasma Alliance and partnering to bring vaccines to Japan.
Company: Takeda Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2020
Type: SR
Pages: 53
Takeda Pharmaceutical Co Ltd
Sustainability Report
The report outlines Takeda's commitment to purpose-led sustainability, focusing on patients, people, and the planet. Key highlights include achieving carbon neutrality for FY2019 through offsets and setting a target for net-zero operations by 2040. The company invested ¥492.4 billion in R&D, focusing on four core therapeutic areas, and reached over 70,000 patients in underserved communities through access programs. Takeda also responded to the COVID-19 pandemic by co-founding the CoVIg-19 Plasma Alliance and partnering to bring vaccines to Japan.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2019
Published
Nov 27, 2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women in Management
Net Zero Target
Employees